SCHEMBL22357902

SCHEMBL22357902

COC(=O)N1CCC(c2nc(-c3ccc4cnn(C(C)C)c4c3)no2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMO Q99835 4/20 0.52
SMN1; SMN2 Q16637 5/20 0.48
LMNA P02545 1/20 0.48
TSHR P16473 1/20 0.48
TUBB4A P04350 4/20 0.46
TUBB P07437 4/20 0.46
TUBA3C P0DPH7 4/20 0.46
TUBA1B P68363 4/20 0.46
TUBA4A P68366 4/20 0.46
TUBB4B P68371 4/20 0.46
TUBB3 Q13509 4/20 0.46
TUBB2A Q13885 4/20 0.46
TUBB8 Q3ZCM7 4/20 0.46
TUBA3E Q6PEY2 4/20 0.46
TUBA1A Q71U36 4/20 0.46
TUBA1C Q9BQE3 4/20 0.46
TUBB6 Q9BUF5 4/20 0.46
TUBB2B Q9BVA1 4/20 0.46
TUBB1 Q9H4B7 4/20 0.46
HTT P42858 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20116833 0.92 SMO (0.51) SMOSMN1; SMN2LMNATSHRTUBB4A
SCHEMBL22358141 0.92 SMN1; SMN2 (0.47) SMOSMN1; SMN2LMNATSHRTUBB4A
SCHEMBL22357909 0.91 SMN1; SMN2 (0.46) SMOSMN1; SMN2LMNATSHRTUBB4A
SCHEMBL22358278 0.91 SMO (0.49) SMOSMN1; SMN2LMNATSHRTUBB4A
SCHEMBL22358127 0.90 GPR119 (0.47) SMOSMN1; SMN2LMNATSHRHTT
SCHEMBL20116047 0.90 SMO (0.46) SMOSMN1; SMN2LMNATSHRTUBB4A
SCHEMBL22357942 0.89 SMO (0.44) SMOSMN1; SMN2LMNATSHRTUBB4A
SCHEMBL22357912 0.89 SMN1; SMN2 (0.44) SMOSMN1; SMN2LMNATSHRTUBB4A
SCHEMBL22358002 0.88 MGLL (0.53) SMOSMN1; SMN2LMNATSHRHTT
SCHEMBL22357908 0.87 SMN1; SMN2 (0.43) SMOSMN1; SMN2LMNATSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 SMO 1858/4885SMN1; SMN2 13/4885LMNA 1966/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 SMO 1858/4885SMN1; SMN2 13/4885LMNA 1966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.